Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide cro
- PDF / 1,487,960 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 12 Downloads / 165 Views
(2020) 19:237
RESEARCH
Open Access
Utilization of statins and LDL-cholesterol target attainment in Turkish patients with type 2 diabetes - a nationwide crosssectional study (TEMD dyslipidemia study) Fahri Bayram1†, Alper Sonmez2†, Cem Haymana3* , Tevfik Sabuncu4, Oguzhan Sitki Dizdar5, Eren Gurkan6, Ayse Kargili Carlioglu7, Kemal Agbaht8, Didem Ozdemir9, Ibrahim Demirci3, Cem Barcin10, Serpil Salman11, Tamer Tetiker12, Mustafa Kemal Balci13, Nur Kebapci14, Canan Ersoy15, Volkan Yumuk16, Peter P. Toth17,18, Ilhan Satman19 and TEMD Study Group
Abstract Background: Attaining acceptable levels of LDL Cholesterol (LDL-C) significantly improves cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus (T2DM). The LDL-C target attainment and the characteristics of patients attaining these targets were investigated in this study. Furthermore, the reasons for not choosing statins and the physicians’ attitudes on the treatment of diabetic dyslipidemia were also examined. Methods: A nationwide, cross-sectional survey was conducted in tertiary centers for diabetes management. Adult patients with T2DM, who were under follow-up for at least a year in outpatient clinics, were consecutively enrolled for the study. LDL-C goals were defined as below 70 mg/dL for patients with macrovascular complications or diabetic nephropathy, and below 100 mg/dL for other patients. Data about lipid-lowering medications were selfreported. Results: A total of 4504 patients (female: 58.6%) were enrolled for the study. The mean HbA1c and diabetes duration was 7.73 ± 1.74% and 10.9 ± 7.5 years, respectively. The need for statin treatment was 94.9% (n = 4262); however, only 42.4% (n = 1807) of these patients were under treatment, and only 24.8% (n = 448) of these patients achieved LDL-C targets. The main reason for statin discontinuation was negative media coverage (87.5%), while only a minority of patients (12.5%) mentioned side effects. Physicians initiated lipid-lowering therapy in only 20.3% of patients with high LDL-C levels. It was observed that the female gender was a significant independent predictor of not attaining LDL-C goals (OR: 0.70, 95% CI: 0.59–0.83). (Continued on next page)
* Correspondence: [email protected] † Fahri Bayram and Alper Sonmez contributed equally to this work. Fahri Bayram and Alper Sonmez are share the first authorship. 3 Department of Endocrinology and Metabolism, University of Health Sciences, Gulhane Training and Research Hospital, Ankara, Turkey Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons li
Data Loading...
